22 peptides tracked
Australia's
Independent
Peptide Register
No vendors. No affiliates. Just data.
Fig. 01
Regulatory Status · October 2026
Retatrutide2
GHK-Cu10
Semaglutide12
Tirzepatide8
BPC-15718
CJC-129515
22
Peptides tracked
40
Prescription providers
52
Observed suppliers
1
Prohibited (S9)
01Intelligence
Peptide Status
TGA scheduling, enforcement trends, and access pathways for each peptide. Updated October 2026.
Editorial position: We recommend accessing peptides through an AHPRA-registered medical practitioner and TGA-licensed compounding pharmacy. This ensures clinical oversight, pharmaceutical-grade compounding, and legal compliance.
Retatrutide
Triple Agonist (GLP-1/GIP/Glucagon)
GHK-Cu
Copper Peptide
Semaglutide
GLP-1 Agonist
Tirzepatide
GLP-1/GIP Agonist
BPC-157
Tissue Repair
CJC-1295
Growth Hormone Secretagogue
Ipamorelin
Growth Hormone Secretagogue
TB-500
Tissue Repair
Melanotan II
Melanocortin Agonist
PT-141 (Bremelanotide)
Melanocortin Agonist
MOTS-c
Mitochondrial Peptide
Thymosin Alpha-1
Immune Modulator
KPV
Anti-inflammatory Peptide
Epithalon
Telomerase Activator
Gonadorelin
Hormonal Support
Dihexa
Cognitive Enhancement
02News
Regulatory Feed
Latest scheduling changes, enforcement actions, and market developments across all tracked peptides.
HeadlineSourceDate
Changes in Gait Speed During a 12-Month Multidisciplinary Obesity Management Program Including Semaglutide: A Real-World Observational Study in Japanese Adults With Musculoskeletal Disorders.Semaglutide
Internal medicine (Tokyo, Japan)15 Oct 2026Outcomes in patients with diabetes, atherosclerotic cardiovascular disease, and heart failure treated with tirzepatide or dulaglutide: SURPASS-CVOT analysis.Tirzepatide
European journal of preventive cardiology15 Oct 2026Real-World Treatment Patterns and Weight Outcomes Before and After a Tirzepatide Price Increase in Over One Million Self-Paying UK Adults With Overweight or Obesity.Semaglutide
Diabetes, obesity & metabolism14 Oct 2026Emerging therapies for knee osteoarthritis.Semaglutide
Nature reviews. Rheumatology14 Oct 2026GLP-1 receptor agonists and hair loss: adverse effect, epiphenomenon, or therapeutic paradox?Tirzepatide
Acta diabetologica14 Oct 2026Detection of CJC-1295 in Equine Plasma by ELISA.CJC-1295
Drug testing and analysis14 Oct 2026Effects of tirzepatide (GIP/GLP-1 dual receptor agonist) on cardiorenal biomarkers and functional capacity in heart failure: a systematic review and meta-analysis.Tirzepatide
The Journal of clinical endocrinology and metabolism13 Oct 2026Tirzepatide use in adolescents with metabolic dysfunction-associated steatotic liver disease (MASLD): A case series.Semaglutide
JPGN reports12 Oct 2026GLP-1RA based treatment in patients with a PCSK1 mutation has profound effects on body weight - two case reports.Tirzepatide
Obesity facts12 Oct 2026The pharmacotherapy for pediatric obesity: insights and challenges from adult weight-loss medicationsRetatrutide
J Diabetes Metab Disord12 Oct 2026Tirzepatide-induced pneumatosis intestinalis: a rare but clinically significant gastrointestinal adverse effect.Tirzepatide
American journal of clinical pathology11 Oct 2026"Ozempic Face" and Facial Aging.Semaglutide
Clinics in dermatology10 Oct 2026Preconception incretin therapy reduces pregnancy and cardiometabolic outcomes in polycystic ovary syndrome.Semaglutide
The Journal of clinical endocrinology and metabolism10 Oct 2026Cardiovascular Risk in SELECT-Eligible MI Patients With Overweight or Obesity: The Western Denmark Heart Registry.Semaglutide
JACC. Advances9 Oct 2026Weight Management in Obesity-Associated Sleep-Disordered Breathing: Mechanisms, Clinical Management, and Emerging Therapies.Tirzepatide
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists9 Oct 2026Tirzepatide persistence, adherence, and dose escalation in a real-world setting with high out-of-pocket costs: a Polish cohort study.Tirzepatide
Advances in medical sciences9 Oct 2026Unapproved GLP-1 Drugs Retatrutide and Zenagamtide Sold Online Are No Bargain.Retatrutide
JAMA9 Oct 2026The therapeutic potential of GLP-1 receptor agonists in central nervous system diseases: immune cell modulation and neuroinflammation.Semaglutide
Expert review of clinical immunology8 Oct 2026Ischemic colitis associated with oral semaglutide with recurrence upon rechallenge.Semaglutide
Revista espanola de enfermedades digestivas8 Oct 2026Beyond body mass index: A contemporary review of obesity and female infertility.Tirzepatide
Clinical and experimental reproductive medicine8 Oct 2026Regulatory Notice
For informational purposes only. TGA scheduling may change without notice. All Schedule 4 peptides require a valid prescription from a registered Australian medical practitioner. This site does not sell, supply, or facilitate access to therapeutic goods. Data compiled from TGA SUSMP, public provider directories, and publicly available review platforms.